Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer

Li, Youquan; Shi, Anhui; Li, Fuhai; Yu, Rong; Zhu, Guangying

doi:10.1007/s11670-011-0129-9

Cited by 4 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, DTX has been shown to be clinically useful as an active agent in CRT treatment regimens involving laryngeal/hypopharyngeal cancers (19). DTX has been used in combination with cisplatin as an agent for CRT in non-small cell lung cancer (20). A phase I/II study involving DTX and cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer has shown that the dose limiting toxicity is radiation esophagitis (21).…”

Section: Introductionmentioning

confidence: 99%

Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells

Miyanaga

Ninomiya

Tsukada

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

Taxanes, paclitaxel and docetaxel (DTX) are anticancer agents that exhibit cytotoxicity by inhibiting microtubule polymerization. They enhance the radiosensitivity of various cancers by blocking the cell cycle in the most radiosensitive G2/M phase. Recently, taxanes have been reported to have different mechanisms of action depending on dose intensity. However, the mechanism of the radio-enhancing effect of DTX in relation to the drug dose intensity is not clearly understood. In the present study, we experimentally investigated the radio-enhancing effects of various concentrations of DTX against esophageal squamous cell cancer (ESCC); KES cells were used for in vitro confirmation of the effective administration schedule for DTX in chemoradiotherapy involving ESCC. DTX enhanced radiation cell killing in a concentration-dependent manner in KES cells. High cytotoxic concentrations (>10 nM) of DTX strongly enhanced radiosensitivity. Low concentrations (<1 nM) of DTX that did not have a cytotoxic effect showed a radio-enhancing effect by inducing DNA double strand breaks and apoptosis after irradiation. Low and high concentrations of DTX induced radiosensitive G0/G1 and G2/M phase arrest, respectively in KES cells. Cells treated with high concentrations of DTX exhibited nuclear aggregation associated with apoptotic change. In contrast, cells treated with low concentrations of DTX displayed multi-nucleation or unequal division. In conclusion, enhancement of the radiosensitivity of ESCC cells by DTX was demonstrated, even using nanomolar concentrations that did not have a cytotoxic effect. DTX has different radio-enhancing mechanisms depending on its concentration. Therefore, weekly administration of DTX might effectively enhance radiation cytotoxicity in the treatment of ESCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells

Miyanaga

Ninomiya

Tsukada

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…N 2 skip lymphatic metastasis may be an earlier stage of lymphatic metastasis in NSCLC and its significance is similar to N l lymph node metastasis. In addition, some scholars proposed that dysregulation of gene expression associated with primary tumor is one of the most important factors influencing lymph node metastasis (20). Prenzel et al found that decreased expression of Bcl-2 and elevated expression of P21 were associated with N 2 skip metastasis in lung cancer (21).…”

Section: Discussionmentioning

confidence: 99%

Analysis of factors influencing skip lymphatic metastasis in pN2 non-small cell lung cancer

Zheng

Guo

et al. 2012

Chin. J. Cancer Res.

View full text Add to dashboard Cite

Objective: Although many clinical studies on skip lymphatic metastasis in non-small cell lung cancer have been reported, the risk factors for skip lymphatic metastasis are still controversy and debatable. This study investigated, by multivariate logistic regression analysis, the clinical features of skip metastasis to mediastinal lymph nodes (N 2 ) in non-small cell lung cancer (NSCLC) patients. Methods:We collected the clinicopathological data of 256 pN 2 -NSCLC patients who underwent lobectomy plus systemic lymph node dissection in Fujian Medical University Union Hospital. The cases in the present study were divided into two groups: skip metastasis (N 2 skip+) and non-skip metastasis (N 2 skip-). A retrospective analysis of clinical pathological features of two groups was performed. To determine an independent factor, multivariate logistic regression analysis was used to identify possible risk factors.Results: A total of 256 pN 2 -NSCLC patients were recruited. The analysis results showed that gender, pathologic types, surgery, pleural involvement, smoking history, age, tumor stages, and differentiation were not statistical significant factors impacting on skip metastasis in pN 2 -NSCLC (P>0.05), whereas tumor size was an independent factor for skip metastasis (P=0.02). Conclusions:The rate of skip lymphatic metastasis increases in pN 2 -NSCLC patients, in accompany with an increased tumor size. [(58.5±9.6) years]. Tumors were located at the upper lobe(n=138, 53.9%), middle lobe (n=13, 5.1%), lower lobe(n=99, 38.7%) and pulmonary hilum (n=6, 2.3%). The pathological types included adenocarcinoma (n=141, 55.1%), squamous cell carcinoma (n=90, 35.2%), adenosquamous cell carcinoma (n=11, 4.3%), large cell carcinoma of lung (n=9, 3.5%), and other primary lung cancers (n=5, 2%) that included atypical carcinoid (n=3), epidermoid carcinoma (n=1), and sarcomatoid carcinoma (n=1). The size of tumors ranged 10-150mm, with an average size of (47.5±21.6) mm. In 256 cases, the total N 1 lymph nodes for pathological examination was present at least 1 group/case, and up to 4 groups/case, with an average number (2.3±0.8) groups/case. Among the 256 cases, there were 44 cases of skip lymphatic metastasis, which were at least 2 groups/case, and up to 4 groups/ case, with an average number (2.4±0.6) groups/case. The other 212 cases non-skip metastasis, which were at least 1 group/case, and up who 4 groups/case, with an average number (2.3±0.8) groups/case. Before surgery, all patients were naive to chemotherapy, without previous cancer history, and with only one localized tumor that had no distant metastasis. In cases that were not suspected of skip metastasis, the number of N 1 lymph nodes for examination was required not less than 2 group/case and the related examinations were carried out to exclude surgery contraindications. Statistical analysisTwo-sided test was used in all statistical tests and P<0.05 was considered statistically significant. Followed by univariate analysis of possible risk factors, multivariate analyses we...

show abstract

Advancements in radiotherapy for lung cancer in China

赵路军

王绿化²

2015

Oncology and Translational Medicine

View full text Add to dashboard Cite

Lung cancer is the leading cause of death due to cancer in China. In recent years, great progress has been made in radiotherapy for lung cancer patients in China. The main advancements include the following aspects: (1) stereotactic ablative radiotherapy for early stage nonsmall cell lung cancer (NSCLC), (2) post-operative radiotherapy for NSCLC, (3) combined chemotherapy and radiotherapy for locally advanced NSCLC, (4) improved radiotherapy for advanced NSCLC, and 5) prediction of radiation-induced lung toxicity.

show abstract

Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer

Cited by 4 publications

References 16 publications

Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells

Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells

Analysis of factors influencing skip lymphatic metastasis in pN2 non-small cell lung cancer

Advancements in radiotherapy for lung cancer in China

Contact Info

Product

Resources

About